Name
Purdue University Globle
NU553 Advanced Pharmacology and Pharmacotherapeutics
Prof. Name
Date
Preparing for the NU553 Unit 6 Exam requires a strong understanding of cardiovascular pharmacology, blood disorders, and evidence-based medication management. The most effective way to prepare is to review drug mechanisms, clinical indications, adverse effects, laboratory monitoring, contraindications, and patient safety considerations. This NU553 Unit 6 study guide covers high-yield topics, including anticoagulants, anemia, hypertension, hyperlipidemia, angina, myocardial infarction, heart failure, and arrhythmias, along with practice questions and rationales to strengthen your clinical reasoning.
Whether you are reviewing lecture materials, preparing for a nursing pharmacology exam, or practicing medication-related questions, understanding why a medication is prescribed and how it affects the body is essential for success.
Thromboembolic disorders develop when blood clots form inside blood vessels and interfere with normal circulation. These conditions include deep vein thrombosis (DVT), pulmonary embolism (PE), and thromboembolic complications associated with atrial fibrillation or mechanical heart valves. Pharmacologic treatment focuses on preventing clot extension, reducing the risk of embolism, and balancing anticoagulation against bleeding risk.
The major anticoagulant classes include unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), warfarin, and direct oral anticoagulants (DOACs). Each medication works differently and has specific monitoring requirements.
| Medication | Mechanism and Important Exam Points |
|---|---|
| Unfractionated heparin (UFH) | Enhances antithrombin activity, inhibiting thrombin and factor Xa. Monitor aPTT or an institution-specific anti-Xa protocol. Protamine sulfate is used for reversal. |
| Low-molecular-weight heparin (LMWH) | Primarily inhibits factor Xa through antithrombin. Routine laboratory monitoring is usually unnecessary, but anti-Xa monitoring may be considered in selected patients. |
| Warfarin | Inhibits vitamin K epoxide reductase, reducing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X. Monitor INR. Vitamin K is a reversal agent. |
| Direct oral anticoagulants (DOACs) | Directly inhibit factor Xa or thrombin, depending on the medication. Routine INR monitoring is not used to measure their anticoagulant effect. |
When studying anticoagulants, focus on the mechanism of action, therapeutic indications, bleeding precautions, drug interactions, renal function, and reversal agents. Patients receiving anticoagulants should be assessed for bleeding, including unusual bruising, hematuria, melena, and prolonged bleeding from minor injuries.
Warfarin has a delayed onset because it reduces the production of clotting factors that are already circulating in the blood. Heparin may be used to provide immediate anticoagulation while warfarin takes effect in situations where bridging is clinically indicated.
A high-yield exam point is that patients with mechanical heart valves, especially mechanical mitral valves, have a high risk of thromboembolism. However, heparin bridging is not automatically required for every patient starting warfarin. The need for bridging depends on the patient’s thromboembolic risk, the type of valve, and the clinical situation.
Students should also remember that warfarin dosing is individualized and that INR targets vary according to the indication. Always distinguish between the need for anticoagulation and the need for bridging.
Antiplatelet drugs prevent platelets from aggregating and are especially important in arterial thrombosis, acute coronary syndrome, and coronary stent management.
Common medications include:
Aspirin
Clopidogrel
Prasugrel
Ticagrelor
Aspirin inhibits platelet cyclooxygenase-1, reducing thromboxane A2 production. Clopidogrel, prasugrel, and ticagrelor inhibit platelet P2Y12 receptors through different mechanisms.
For the NU553 exam, review dual antiplatelet therapy, bleeding precautions, medication interactions, and perioperative considerations. Patients receiving antiplatelet therapy after coronary stenting may require treatment for a specific duration based on their clinical condition and bleeding risk.
Anemia occurs when the blood does not have enough healthy red blood cells or hemoglobin to adequately support oxygen delivery. Diagnosis requires consideration of the patient’s symptoms, medical history, complete blood count (CBC), red blood cell indices, and additional laboratory testing.
For exam preparation, learn to connect each anemia type with its characteristic laboratory findings and treatment.
Iron deficiency anemia is commonly associated with inadequate iron intake, blood loss, malabsorption, or increased iron requirements. It typically produces microcytic, hypochromic red blood cells.
Common laboratory findings include:
Low hemoglobin and hematocrit.
Low ferritin, particularly when iron stores are depleted.
Low serum iron.
Increased total iron-binding capacity (TIBC).
Low transferrin saturation.
Reduced mean corpuscular volume (MCV) in established microcytic anemia.
Treatment may include oral iron supplementation or intravenous iron when oral therapy is ineffective, poorly tolerated, or unsuitable. Nurses should teach patients that oral iron may cause constipation, nausea, and dark stools. Vitamin C may improve iron absorption, while calcium and certain medications can interfere with absorption.
Vitamin B12 deficiency usually causes megaloblastic, macrocytic anemia. It may result from inadequate intake, malabsorption, pernicious anemia, or gastrointestinal conditions affecting vitamin absorption.
Important findings include:
Macrocytosis.
Elevated methylmalonic acid.
Elevated homocysteine.
Possible neurologic symptoms, such as numbness, tingling, impaired balance, or cognitive changes.
Neurologic manifestations are a major exam clue. Treatment depends on the cause and severity of deficiency. Intramuscular cyanocobalamin may be used for patients with significant deficiency or neurologic involvement, while oral therapy may be appropriate for selected patients.
Folate deficiency also produces macrocytic, megaloblastic anemia. It may occur because of inadequate dietary intake, malabsorption, increased requirements, or medications that interfere with folate metabolism.
Typical laboratory findings include:
Elevated MCV.
Elevated homocysteine.
Normal methylmalonic acid.
Folic acid supplementation is the usual treatment. However, vitamin B12 deficiency should be excluded before treating unexplained megaloblastic anemia with folic acid alone because folate can improve the anemia while neurologic damage from untreated B12 deficiency continues.
The NU553 Unit 6 exam may also include anemia of chronic disease, chronic kidney disease-associated anemia, sickle cell disease, thalassemia, and aplastic anemia.
For each disorder, review:
Underlying pathophysiology.
Characteristic CBC and laboratory findings.
Pharmacologic and supportive treatment.
Contraindications and adverse effects.
Monitoring and patient education.
Hypertension is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and other cardiovascular complications. Pharmacologic management is based on blood pressure measurements, cardiovascular risk, comorbidities, and evidence-based treatment recommendations.
The following medication classes are important for NU553 exam preparation:
| Drug class | High-yield points |
|---|---|
| ACE inhibitors | Reduce angiotensin II production. Can cause cough, hyperkalemia, and angioedema. Monitor renal function and potassium. |
| ARBs | Block angiotensin II receptors. May cause hyperkalemia and renal function changes. Cough is less common than with ACE inhibitors. |
| Thiazide diuretics | Increase sodium and water excretion. Can cause hypokalemia, hyponatremia, and hyperuricemia. |
| Loop diuretics | Promote substantial diuresis. Monitor potassium, magnesium, fluid balance, and renal function. |
| Calcium channel blockers | Dihydropyridines cause vasodilation and may produce peripheral edema. Non-dihydropyridines can reduce heart rate and contractility. |
| Beta blockers | Reduce heart rate and myocardial oxygen demand. May cause bradycardia, fatigue, and bronchospasm with nonselective agents. |
| Mineralocorticoid receptor antagonists | Useful in selected patients with resistant hypertension and heart failure. Monitor potassium and renal function. |
ACE inhibitors commonly cause a persistent, dry cough because of increased bradykinin levels. If a patient develops this adverse effect, an ARB may be considered when clinically appropriate.
Dihydropyridine calcium channel blockers, such as amlodipine, frequently cause peripheral edema. This occurs because arteriolar dilation increases capillary hydrostatic pressure, allowing fluid to move into surrounding tissues.
ACE inhibitors, ARBs, and potassium-sparing diuretics require careful monitoring of serum potassium and renal function. Hyperkalemia and acute kidney injury are important safety concerns.
Hyperlipidemia refers to abnormal levels of lipids in the blood, including cholesterol and triglycerides. Management focuses on reducing atherosclerotic cardiovascular disease (ASCVD) risk through lifestyle changes and medications when indicated.
Low-density lipoprotein (LDL) transports cholesterol to peripheral tissues. Elevated LDL-C contributes to atherosclerotic plaque formation and is a major target of lipid-lowering treatment.
High-density lipoprotein (HDL) participates in reverse cholesterol transport, carrying cholesterol toward the liver. Although HDL has important physiologic functions, HDL levels alone should not be used to determine cardiovascular risk or guide treatment.
ASCVD risk assessment helps clinicians determine the intensity of preventive treatment. Important considerations include age, blood pressure, diabetes, smoking, cholesterol levels, and previous cardiovascular disease.
Coronary artery calcium (CAC) scoring may help guide statin decisions in selected adults when the need for treatment remains uncertain. It is not necessary for every patient.
Important medications include statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, fibrates, and selected triglyceride-lowering agents.
Statins are the primary medications for reducing LDL-C and preventing cardiovascular events in many patients. Students should understand their mechanism, muscle-related adverse effects, liver considerations, and potential drug interactions.
Ezetimibe decreases intestinal cholesterol absorption. PCSK9 inhibitors substantially lower LDL-C and may be used in selected patients who require additional LDL reduction.
Bile acid sequestrants can increase triglyceride levels. They should generally be avoided in patients with significantly elevated triglycerides, especially when triglycerides are 300 mg/dL or higher, because they may worsen hypertriglyceridemia.
Angina occurs when myocardial oxygen demand exceeds oxygen supply. Pharmacologic treatment aims to relieve symptoms, reduce cardiac workload, improve coronary blood flow when appropriate, and prevent cardiovascular events.
Important medications include:
Nitroglycerin.
Beta blockers.
Calcium channel blockers.
Ranolazine.
Nitroglycerin produces vasodilation and reduces myocardial oxygen demand, particularly through venodilation. Sublingual nitroglycerin is used for rapid relief of acute anginal symptoms.
Beta blockers reduce heart rate and contractility, lowering myocardial oxygen demand. Calcium channel blockers may be used for symptom management, particularly when beta blockers are unsuitable or when vasospasm is involved.
Ranolazine is used for chronic angina and works through a different mechanism from traditional vasodilators. It is important to review its potential to prolong the QT interval and its drug interactions.
Continuous exposure to nitrates can reduce their effectiveness. A daily nitrate-free interval is commonly prescribed for long-acting nitrate regimens to reduce tolerance. The exact schedule depends on the formulation and prescription, but an interval of approximately 10 to 12 hours is a commonly tested concept.
Patients should also understand that phosphodiesterase-5 inhibitors, such as sildenafil, can cause dangerous hypotension when combined with nitrates.
Following myocardial infarction, treatment aims to reduce recurrent cardiovascular events and improve long-term outcomes. Depending on the patient’s condition, management may include:
High-intensity statin therapy.
Antiplatelet therapy.
Beta blockers when indicated.
ACE inhibitors or ARBs in appropriate patients.
Smoking cessation.
Blood pressure and diabetes management.
Cardiac rehabilitation and lifestyle modification.
The specific medication regimen depends on left ventricular function, kidney function, blood pressure, comorbidities, and other clinical factors.
Heart failure occurs when the heart cannot adequately meet the body’s circulatory demands. Treatment focuses on improving symptoms, reducing hospitalizations, and, when supported by evidence, decreasing mortality.
For many patients with heart failure with reduced ejection fraction (HFrEF), guideline-directed medical therapy includes four foundational medication groups:
Angiotensin receptor-neprilysin inhibitor (ARNI), or an ACE inhibitor or ARB when appropriate.
Evidence-based beta blocker.
Mineralocorticoid receptor antagonist.
Sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Loop diuretics are frequently used to manage fluid overload and congestion. They improve symptoms but are not considered a substitute for the foundational therapies that provide disease-modifying benefits.
Important monitoring parameters include blood pressure, heart rate, kidney function, potassium, fluid status, and signs of worsening heart failure.
ARNIs, ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists may affect renal function and potassium levels. Patients should be monitored for hypotension, hyperkalemia, and other medication-specific adverse effects.
Verapamil is a nondihydropyridine calcium channel blocker with negative inotropic effects. It can reduce myocardial contractility and may worsen systolic heart failure. For this reason, it is generally avoided in patients with HFrEF.
This is a high-yield NU553 exam concept: Verapamil decreases cardiac contractility and may worsen heart failure with reduced ejection fraction.
Arrhythmias are abnormal heart rhythms that may arise from problems with impulse formation or conduction. Antiarrhythmic medications require careful monitoring because some can cause serious adverse effects, including proarrhythmia.
| Class | Main mechanism | Examples |
|---|---|---|
| Class I | Sodium channel blockade | Flecainide, lidocaine |
| Class II | Beta-adrenergic blockade | Metoprolol, esmolol |
| Class III | Potassium channel blockade | Amiodarone, sotalol |
| Class IV | Calcium channel blockade | Verapamil, diltiazem |
Students should review ECG effects, QT interval changes, bradycardia, drug interactions, and organ-specific toxicity.
Flecainide is a Class IC antiarrhythmic that slows cardiac conduction. It should generally be avoided in patients with significant structural heart disease, particularly those with prior myocardial infarction or coronary artery disease in the relevant clinical context, because of the risk of life-threatening ventricular proarrhythmia.
The key exam association is:
Flecainide + significant structural heart disease = increased proarrhythmic risk.
Use the following questions to test your knowledge of cardiovascular pharmacology and hematologic disorders.
Which patient is most likely to require heparin bridging when initiating warfarin therapy?
A. A patient with low-risk atrial fibrillation and no additional risk factors.
B. A patient with a mechanical mitral valve beginning warfarin therapy.
C. A patient taking warfarin for a remote history of DVT.
D. A patient with a normal INR and no indication for anticoagulation.
Correct Answer: B. A patient with a mechanical mitral valve beginning warfarin therapy.
Rationale: Mechanical mitral valves are associated with a high risk of thromboembolism. Heparin may provide immediate anticoagulation while warfarin takes effect. Bridging is based on thromboembolic risk and the clinical indication; it is not required for every patient starting warfarin.
A patient has macrocytic anemia, peripheral neuropathy, elevated methylmalonic acid, and elevated homocysteine. Which treatment is most appropriate?
A. Oral ferrous sulfate.
B. Folic acid alone without further evaluation.
C. Vitamin B12 replacement, with parenteral therapy considered for significant deficiency or neurologic involvement.
D. Erythropoietin as the first-line treatment.
Correct Answer: C. Vitamin B12 replacement, with parenteral therapy considered for significant deficiency or neurologic involvement.
Rationale: Elevated methylmalonic acid and neurologic manifestations strongly suggest vitamin B12 deficiency. Patients with neurologic symptoms may require intramuscular cyanocobalamin, depending on the cause and severity of deficiency.
Which antihypertensive medication class is most commonly associated with a persistent, dry cough?
A. Angiotensin receptor blockers.
B. ACE inhibitors.
C. Thiazide diuretics.
D. Dihydropyridine calcium channel blockers.
Correct Answer: B. ACE inhibitors.
Rationale: ACE inhibitors increase bradykinin concentrations, which may produce a persistent, nonproductive cough. ARBs are less likely to cause this adverse effect.
Which medication class commonly causes peripheral edema through arteriolar vasodilation?
A. Beta blockers.
B. ACE inhibitors.
C. Dihydropyridine calcium channel blockers.
D. Loop diuretics.
Correct Answer: C. Dihydropyridine calcium channel blockers.
Rationale: Medications such as amlodipine cause arteriolar dilation. This increases capillary hydrostatic pressure and may lead to lower-extremity edema.
Which lipid-lowering medication should generally be avoided in a patient with significantly elevated triglycerides, such as 350 mg/dL?
A. Ezetimibe.
B. A statin.
C. Bile acid sequestrants.
D. A PCSK9 inhibitor.
Correct Answer: C. Bile acid sequestrants.
Rationale: Bile acid sequestrants may increase triglyceride concentrations. They are generally avoided when triglycerides are significantly elevated.
What is a commonly used strategy for preventing nitrate tolerance in a patient prescribed long-acting nitrates?
A. Take the medication continuously throughout the day without interruption.
B. Double the dose whenever angina occurs.
C. Maintain a daily nitrate-free interval as prescribed.
D. Take nitrates with a phosphodiesterase-5 inhibitor.
Correct Answer: C. Maintain a daily nitrate-free interval as prescribed.
Rationale: Continuous nitrate exposure may lead to tolerance. A scheduled nitrate-free interval helps preserve therapeutic effectiveness. Nitrates must not be combined with phosphodiesterase-5 inhibitors because of the risk of severe hypotension.
Which medication should generally be avoided in HFrEF because of its negative inotropic effects?
A. Dapagliflozin.
B. Spironolactone.
C. Verapamil.
D. Furosemide.
Correct Answer: C. Verapamil.
Rationale: Verapamil reduces myocardial contractility and may worsen systolic heart failure. It is generally avoided in HFrEF.
Which condition is an important contraindication or major safety concern when considering flecainide?
A. Mild seasonal allergies.
B. Significant structural heart disease.
C. Iron deficiency without cardiac disease.
D. Controlled hypothyroidism.
Correct Answer: B. Significant structural heart disease.
Rationale: Flecainide can increase the risk of serious ventricular arrhythmias in patients with structural heart disease, including relevant coronary artery disease or prior myocardial infarction.
The following concepts are especially important when reviewing cardiovascular pharmacology and hematology:
Warfarin has a delayed onset, and bridging is used when clinically indicated in patients at high thromboembolic risk.
Vitamin B12 deficiency is associated with elevated methylmalonic acid, macrocytic anemia, and possible neurologic symptoms.
ACE inhibitors commonly cause a persistent dry cough.
Dihydropyridine calcium channel blockers may cause peripheral edema.
Bile acid sequestrants can worsen elevated triglycerides.
Long-acting nitrates require a prescribed nitrate-free interval to reduce tolerance.
Verapamil is generally avoided in HFrEF because of negative inotropic effects.
Flecainide should generally be avoided in significant structural heart disease because of proarrhythmic risk.
ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists require attention to renal function and potassium.
Heart failure treatment should be reviewed in terms of symptom relief, hospitalization reduction, and disease-modifying therapy.
Begin with anticoagulants, antiplatelet medications, anemia laboratory findings, antihypertensive drug classes, lipid-lowering therapy, heart failure medications, and antiarrhythmic drugs. Focus on mechanisms, adverse effects, monitoring, contraindications, and clinical decision-making.
Heparin provides immediate anticoagulation, while warfarin takes several days to reduce the activity of vitamin K-dependent clotting factors. Bridging is used when the patient’s thromboembolic risk and clinical indication justify it.
Both may cause macrocytic anemia and elevated homocysteine. Vitamin B12 deficiency also increases methylmalonic acid and may cause neurologic manifestations, which are not typical of folate deficiency.
ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists commonly require monitoring of serum potassium and renal function. Diuretics may also require electrolyte and kidney function monitoring, depending on the medication and patient condition.
Verapamil reduces myocardial contractility. In patients with reduced ejection fraction, this negative inotropic effect may worsen systolic dysfunction and contribute to heart failure decompensation.
Flecainide can cause serious proarrhythmia in patients with significant structural heart disease. Patient selection and appropriate cardiac evaluation are essential before use.
American College of Cardiology. (n.d.). Guidelines and clinical resources. https://www.acc.org/guidelines
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Supplement_1). https://diabetesjournals.org/care
Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (Eds.). (2023). Goodman & Gilman’s the pharmacological basis of therapeutics (14th ed.). McGraw Hill. https://accessmedicine.mhmedical.com
Katzung, B. G. (2024). Basic & clinical pharmacology (16th ed.). McGraw Hill. https://accessmedicine.mhmedical.com
McCance, K. L., & Huether, S. E. (2023). Pathophysiology: The biologic basis for disease in adults and children (9th ed.). Elsevier. https://www.elsevier.com
U.S. Department of Veterans Affairs, & U.S. Department of Defense. (2020). VA/DoD clinical practice guideline for the management of stroke rehabilitation. https://www.healthquality.va.gov
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/ADA/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
Yancy, C. W., Jessup, M., Bozkurt, B., et al. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation, 136(6), e137–e161. https://doi.org/10.1161/CIR.0000000000000509
